Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

OMB APPROVAL									
OMB Number: 3235-028									
Estimated average burden									
hours per response	9: 0.5								

					01.56	ection 3	O(II) OI I	ine ir	ivesi	ment	Coi	mpany Act	01 194	.0						
Name and Address of Reporting Person* Crockett Thomas Andrew				2. Issuer Name and Ticker or Trading Symbol KalVista Pharmaceuticals, Inc. [KALV]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) C/O KALVISTA PHARMACEUTICALS, INC. 55 CAMBRIDGE PARKWAY, SUITE 901E				3. Date of Earliest Transaction (Month/Day/Year) 03/09/2022									\dashv	X	Office	,	EO	Other (specify below)		
(Street) CAMBR (City)	IDGE M	A 0	2142 (ip)		4. If Amendment, Date of Original Filed (Month/Day/Year)									. Indiv ine) X	dual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Table	I - Non-D	eriva	tive S	Secur	ities /	Acq	uire	ed, D)is	posed o	of, or	Benefic	ially	Own	ed			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye			2A. Deemed Execution Date, if any (Month/Day/Year		n Date,	Tr	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 au				nd 5) Secur Benef		icially d Following	6. Own Form: I (D) or Indirect (Instr. 4	Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Co	Code V		Amount ((A) or (D)	Price		Transaction(s) (Instr. 3 and 4)		(,	(111341. 4)
Common Stock 03/09/202			9/2022	2			S	(1)		1	10,000	D	\$17.06	93(2)	11	14,670	Г)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security			ate,	Transaction of Code (Instr. 8) Se Ac (A' Dis		5. Num of Derivat Securit Acquir (A) or Dispos of (D) (Instr. 3 and 5)	tive ties ed ed	iration	xercisable and n Date ay/Year)		Am Sec Un Der Sec	itle and ount of urities lerlying ivative urity (Instr. d 4)			9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ow Fo Dir or (I)	vnership rm: ect (D) Indirect (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

Explanation of Responses:

- 1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$17.00 to \$17.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

Date Exercisable

Remarks:

/s/ Benjamin L. Palleiko, 03/11/2022 Attorney-in-Fact

** Signature of Reporting Person Date

Number

of Shares

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.